このエントリーをはてなブックマークに追加


ID 64370
JaLCDOI
フルテキストURL
77_1_105.pdf 1.91 MB
著者
Iwasaki, Yoshiaki Health Service Center, Okayama University ORCID Kaken ID publons researchmap
Higuchi, Chigusa Health Service Center, Okayama University
抄録
The inactivated coronavirus disease 2019 vaccine CoronaVac has not been approved in Japan. Little information is available on cases in Japan in which an approved mRNA vaccine was administered as the initial (first or second) dose after two doses of CoronaVac. Furthermore, the safety and efficacy of this combination are not established. We here evaluated the safety and efficacy in a patient who showed an antibody response to an approved vaccine, mRNA-1273, after a previous vaccination with CoronaVac. The adverse events consisted of only mild local and systemic common reactions and were transient. In addition, a strong and persistent antibody response was observed.
キーワード
coronavirus disease 2019
severe acute respiratory syndrome coronavirus 2
vaccine
adverse events
antibody response
Amo Type
Case Report
出版物タイトル
Acta Medica Okayama
発行日
2023-02
77巻
1号
出版者
Okayama University Medical School
開始ページ
105
終了ページ
109
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
英語
著作権者
Copyright Ⓒ 2023 by Okayama University Medical School
論文のバージョン
publisher
査読
有り
PubMed ID
Web of Science KeyUT